Financial Survey: MindWalk (NASDAQ:HYFT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
Analyzing Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & Palatin Technologies (PINK:PTNT) Critical Analysis
Head-To-Head Review: AngioSoma (OTCMKTS:SOAN) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
Evofem Biosciences (NASDAQ:EVFM) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Head-To-Head Survey
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript
Calliditas Interim Report January to June 2024
Number of shares and votes in Calliditas Therapeutics
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders
STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALT
STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALT
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas provides setanaxib patent update
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger and Expiring Tender Offer - AKLI and CALT
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB – CALT
SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate MODN, CALT
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB - CALT
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
Calliditas Therapeutics' stock surges after $1.1 billion takeover bid
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders
Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billion
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
Calliditas Therapeutics AB (publ) (CALT) Q1 2024 Earnings Call Transcript
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
Calliditas Therapeutics' 2023 Annual Report Published
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
Calliditas Therapeutics to Attend Investor Conferences in March
Calliditas Therapeutics AB (publ) (CALT) Q4 2023 Earnings Call Transcript
Calliditas Year-end report, January - December 2023
Invitation to the presentation of Calliditas´ Year-end report January - December 2023
Calliditas provides patent update
Calliditas Therapeutics provides business update ahead of JP Morgan conference
Calliditas Therapeutics appoints Maria Törnsén as President North America
Calliditas to present at JP Morgan Healthcare Conference